| 查看: 568 | 回复: 0 | |||
zlwcw木虫 (著名写手)
|
[交流]
Pharmaron to Host Merck Serono Research and Development Laboratory in China
|
|
Pharmaron to Host Merck Serono Research and Development Laboratory in China - Wednesday, September 14, 2011 BEIJING (Business Wire) - Pharmaron announced a strategic partnership with Merck Serono, the biopharmaceutical division of Merck KGaA, Germany. In the framework of this partnership, Pharmaron’s new campus in the Beijing Economic and Technological Development Area (BDA) will serve as home to Merck Serono’s China R&D Laboratory. The focus of this laboratory will be clinical bioanalysis and biomarker characterization, allowing for the identification of gene mutations among the Chinese population, early detection of disease processes, and development of personalized medicines for cancer and neurodegenerative diseases. Pharmaron, a leading integrated CRO in the US and China with expertise from discovery to IND, recently completed the first phase of its new Beijing campus, which boasts over 600,000 ft2. This new campus houses Pharmaron’s elaborate drug discovery services area including chemistry, DMPK, biology, pharmacology and GLP Bioanalysis. On August 31, 2011, Merck Serono and Pharmaron celebrated the opening ceremony of Merck Serono’s China R&D Laboratory as the beginning of this long-term collaboration between the two companies. Dr. Boliang Lou, Pharmaron Chairman and CEO, spoke jubilantly of this strategic relationship with Merck Serono in China, “This is an important day in Pharmaron’s history. We have always envisioned building a new R&D campus and inviting the world’s top scientists to collaborate with Pharmaron. Together, with world-leading drug R&D companies, we will contribute to advance research against devastating diseases.” Dr. Lou also commented, “Today, this dream has come true. Through this unique partnership, we are providing Merck Serono with a favorable environment as well as qualified staff to lead their drug development programs for local and regional clinical trials against local diseases and unmet medical needs.” Joining Dr. Lou and Pharmaron were senior Beijing government officials, including Deputy Mayor Mr. Zhongwen Gou, as well as a group of delegates from Merck Serono. The Merck Serono team was led by Dr. Stefan Oschmann, President of Merck Serono, Mr. Wayne Paterson, Executive Vice President of Emerging Markets of Merck Serono, Dr. Howard Sui, Managing Director of Merck Serono China, and Ms. Jenny Wu, Site Head and Chief Medical Officer of R&D of Merck Serono China. |
回复此楼» 猜你喜欢
参比制剂，自己做的PK数据与IF资料报道的数据相差很大
已经有2人回复
-
祈求中本子
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有211人回复
-
各位大佬，H口面上什么时候会评？？？
已经有30人回复
-
[求助] 流式死活染 & 单细胞门控设置被质疑，如何优化并解释？
已经有1人回复
-
蛋白稳定性实验与功能实验不一致
已经有11人回复
-
第4年了，马上40了，可能我与国基确实无缘吧。。。
已经有12人回复
-
2026年申博药学专业
已经有1人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
博士研究生招生
已经有0人回复
找到一些相关的精华帖子，希望有用哦~
research associate如何翻译
已经有15人回复
- 急，申请research master 教授让我给他打电话
已经有5人回复
- Accounts of Chemical Research最新综述：二维软材料---氧化石墨烯的另一面
已经有314人回复
- research plan 和外导的CV分别是5页和3页吗？
已经有20人回复
- 关于statement of research interest
已经有8人回复
- 【求助】请问赴美research associate J1 签证时都要准备哪些材料？
已经有5人回复
- 【求助】有多少人的research proposal是外导写的
已经有50人回复
点击这里搜索更多相关资源科研从小木虫开始，人人为我，我为人人